(07/15/16) adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:
• 30 kg/m2 or greater (obese) or
• 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition, (e.g., hypertension, dyslipidemia, type 2 diabetes)
Limitations of Use:
• The safety and efficacy of coadministration with other products for weight loss have not been established
• The effect of BELVIQ XR on cardiovascular morbidity and mortality has not been established.